logo

Seattle Genetics Inc. (SGEN)



Trade SGEN now with
  Date
  Headline
6/29/2020 5:02:21 PM Seattle Genetics Announces Positive Topline Results From Phase 2 Trial Of Tisotumab Vedotin In Cervical Cancer
6/18/2020 8:05:02 AM Seattle Genetics Begins Phase 1 Clinical Trials For Two Novel Antibody-Based Drug Candidates
6/1/2020 7:05:38 AM William Blair Reiterates Seattle Genetics Inc. (SGEN) At Outperform
5/29/2020 8:07:36 AM Seattle Genetics Reports Positive Results From Exploratory Analyses Of HER2CLIMB For TUKYSA
5/18/2020 8:02:52 AM Seattle Genetics To Feature Antibody-Drug Conjugate Innovation And Targeted Therapy Programs At AACR Meeting
5/14/2020 8:09:13 AM Seattle Genetics: ADCETRIS Receives European Commission Approval To Treat Adult Patients With Previously Untreated SALCL
5/12/2020 8:03:10 AM Seattle Genetics Announces Approval Of TUKYSA In Switzerland For Patients With Metastatic HER2-Positive Breast Cancer
4/30/2020 4:08:19 PM Seattle Genetics Q1 Loss/share $0.98 Vs. Loss $0.08 Year Ago
3/3/2020 7:17:54 AM William Blair Reiterates Seattle Genetics Inc. (SGEN) At Outperform
3/2/2020 8:04:29 AM Seattle Genetics Cancels Presentation And Webcast At Cowen 40th Annual Healthcare Conference
2/19/2020 8:22:05 AM Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For PADCEV(tm) With Pembrolizumab
2/11/2020 8:04:36 AM Seattle Genetics And Astellas Pharma Announce Updated Results From Phase 1b/2 Clinical Trial EV-103